Sanctions against Russia adopted in the summer of 2017 will result in aggravation of long-term foreign exchange funding for the Russian economy, in an increase of short-term financial resources in the market and intensification of the speculative nature of Russia’s financial market. The article considers some of the possible measures that Russian regulators and businesses need to take in order to ensure market stability and minimize the negative effects of sanctions for themselves.

Considering the trends of the Russian pharmaceutical industry development, we should bear in mind the existing external constraints, in the first place it is necessary to highlight the need to comply with the WTO rules and regulations, as well as the growing political and military pressure, intensifying economic sanctions against Russia from the part of the world leading countries. In this context, the article discusses the current state of the Russian pharmaceutical industry, strategic options of its development and the concomitant risks.